comparemela.com
Home
Live Updates
MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability : comparemela.com
MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial
Related Keywords
Germany ,
Boston ,
Massachusetts ,
United States ,
Canada ,
Munich ,
Bayern ,
Planegg ,
Kaitlyn Nealy ,
Thomas Biegi ,
Julia Neugebauer ,
Jean Paul Kress ,
Morphosys Agview ,
Exchange Commission ,
Us Communications ,
Linkedin ,
Xencor Inc ,
Twitter ,
Drug Administration ,
Financial Liabilities ,
Chief Executive Officer ,
Antibody Dependent Cell Mediated Cytotoxicity ,
Antibody Dependent Cellular Phagocytosis ,
Morphosy Annual Report ,
Investor Relations ,
Morphosys ,
Reports ,
Reliminary ,
022 ,
Monjuvi ,
Product ,
Sales ,
Rovides ,
023 ,
Financial ,
Guidance ,
Educes ,
Liability ,
comparemela.com © 2020. All Rights Reserved.